Dear {{TableStart:Case}}{{Contact Name: Salutation 1}} {{Contact Name: First Name 1}} {{Contact Name: Last Name 1}}{{TableEnd:Case}},

I hope this email finds you well.

We recently received a request for the Onco*type* DX® Prostate Cancer Assay for patient {{TableStart:Case}}{{Patient\_Initials}} [DOB: {{DOB\@ MM/dd/yyyy}}{{TableEnd:Case}}] on a TURP specimen, as the subsequent biopsy was devoid of tumor.

We have recently reviewed the GPS issued for TURP samples in comparison with TRUS biopsies, and concluded the following:

1. The random sampling method for TRUS biopsies produces better tumor representation for the Onco*type* DX® Prostate Cancer Assay.  
2. Biological differences between TRUS and TURP samples may affect the GPS values.  
3. Differences in reference gene expression in TURP specimens may result in a skewed baseline gene expression.

In light of the above, Genomic Health is no longer accepting TURP specimens for submission, as the likelihood of favorable pathology reported by the assay would not accurately reflect this patient’s risk. We would therefore respectfully recommend cancellation of this particular order.

Please feel free to contact us if you wish to discuss the utility behind the Prostate Cancer Assay or wish to discuss this case further.

Thank you in advance for your time.

Best regards,

{{USER\_NAME}}

CE Team Member  
Customer Service

Genomic Health, Inc.®

**Onco*type* DX**® **Prostate Cancer Assay**

Phone:  877-ONCOTYPE (877-662-6897)

Fax:  650-362-6487